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Abstract
Atypical teratoid rhabdoid tumors (AT/RT) are characterized by mutations and 
subsequent inactivation of SMARCB1 (INI1, hSNF5), a predilection for very 
young children and an unfavorable outcome. The European Registry for rhab-
doid tumors (EU- RHAB) was established to generate a common European da-
tabase and to establish a standardized treatment regimen as the basis for phase 
I/II trials. Thus, genetic analyses, neuropathologic and radiologic diagnoses, and 
a consensus treatment regimen were prospectively evaluated. From 2005 to 2009, 
31 patients with AT/RT from four countries were recruited into the registry 
study Rhabdoid 2007 and treated with systemic and intraventricular chemo-
therapy. Eight patients received high- dose chemotherapy, 23 radiotherapy, and 
17 maintenance therapy. Reference evaluations were performed in 64% (genetic 
analyses, FISH, MLPA, sequencing) up to 97% (neuropathology, INI1 stain). 
Germ- line mutations (GLM) were detected in 6/21 patients. Prolonged overall 
survival was associated with age above 3 years, radiotherapy and achievement 
of a complete remission. 6- year overall and event- free survival rates were 46% 
(±0.10) and 45% (±0.09), respectively. Serious adverse events and one treatment- 
related death due to insufficiency of a ventriculo peritoneal shunt (VP-shunt) 
and consecutive herniation were noted. Acquisition of standardized data includ-
ing reference diagnosis and a standard treatment schedule improved data quality 
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Introduction
The development of specific diagnostic measures including 
immunohistochemistry and molecular genetics has led to 
a precise definition of the entity rhabdoid tumors [1]. 
The majority of rhabdoid tumors demonstrate mutations 
in SMARCB1 (INI1, hSNF5) [2, 3] and rarely SMARCA4 
(BRG1) [4]. Survival remains unsatisfactory due to the 
aggressive nature of the disease and ranges from 15% to 
40% even with intensive multimodality therapy [5, 6]. 
Dufour et al. report 58 nonuniformly treated patients 
with atypical teratoid rhabdoid tumor (AT/RT, 1998–2008) 
with a median overall survival (OS) of 9 months [7]. 
Chi et al. demonstrated a promising 2- year OS of 70% 
treated in a prospective protocol [8].
The implementation of the European registry for rhabdoid 
tumors (EU- RHAB) – was intended to prospectively collect 
comprehensive data on consistently treated children with 
AT/RT across several European countries. Data collection 
was initiated in 2005 with centers mainly from Germany 
and Austria but also Scandinavia and Spain. The registry 
provides basic clinical data and a system of high- quality 
reference diagnostics and expert counseling for diagnostic 
and therapeutic measures. Thus, EU- RHAB was an innova-
tion in AT/RT research at the time of initiation despite 
the fact that the quality of resulting data may not entirely 
be comparable to a controlled clinical trial. Children with 
rare diseases and a risk profile, which makes a controlled 
clinical trial difficult, have the same rights for a standard-
ized treatment with the best available scientific evidence of 
activity. The treatment schedule Rhabdoid 2007, specifically 
designed for rhabdoid tumors, comprised elements including 
anthracyclines, intraventricular methotrexate and early start 
of radiotherapy (RT), all of which have previously been 
described as promising tools in this entity [6, 9].
Materials and Methods
From 06/2005 to 03/2009 a total of 35 patients with a 
centrally confirmed diagnosis of AT/RT were registered 
to EU- RHAB. Thereof 31 patients were treated according 
to the Rhabdoid 2007 schedule. Eight patients received 
high- dose chemotherapy (HDCT) with autologous stem 
cell transplantation following induction chemotherapy at 
the treating physicians discretion. Results for these eight 
patients have partly been reported [10]. Inclusion criteria 
were diagnosis of an AT/RT as confirmed by negative 
INI1 staining and typical neuropathological features as 
confirmed by a reference neuropathologist, age below 
18 years of age and the presence of informed consent by 
the legal guardians to contribute patient- associated data.
EU- RHAB including Rhabdoid 2007 has received con-
tinuous approval by the Ethics Committee of the University 
of Münster (ID 2009- 532- f- S).
Diagnostic measures
Reference neuropathology including immunohistochemistry 
of SMARCB1 was performed according to WHO criteria 
on formalin- fixed paraffin- embedded (FFPE) tumor tissue 
[1]. Staging procedures such as evaluation of lumbar cer-
ebrospinal fluid (CSF) was in accordance with the Chang 
classification [11]. Neuroradiologic response was evaluated 
according to criteria of the German National Reference 
Center for Neuroradiology in Würzburg, Germany [12]. 
DNA was derived from FFPE tumor material and peripheral 
blood cells, and analyzed for somatic and germ- line genetic 
changes in SMARCB1 (SMARCA4) to identify tumor associ-
ated and constitutional aberrations. Fluorescence- in situ 
hybridization (FISH), multiplex ligation- dependent probe 
amplification (MLPA), and sequencing were performed at 
reference centers in Hamburg and Kiel as described [13, 
14]. FISH was performed on fixed unstained slides of periph-
eral blood smears and tumor sections of FFPE material.
Treatment
Rhabdoid 2007 comprised postoperative chemotherapy with 
a total of nine courses including five alternating courses 
of vincristine, cyclophosphamide, doxorubicin (VCD) and 
four of ifosfamide, carboplatinum, etoposide (ICE) every 
21 days (Fig. 1). Age- adjusted intraventricular methotrex-
ate (MTX) or triple chemotherapy (MTX/cytarabine/hydro- 
cortisone) applied via Ommaya or Rickham reservoir was 
recommended with systemic chemotherapy until the start 
of radiotherapy. The suggested maintenance therapy (MT) 
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along with a survival benefit. Treatment was feasible with significant but man-
ageable toxicity. Although our analysis is biased due to heterogeneous adherence 
to therapy, EU- RHAB provides the best available basis for phase I/II clinical 
trials.
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consisted of eight cycles of trofosfamide/idarubicin (TI) 
and trofosfamide/etoposide (TE) every 3 weeks.
Conformal radiotherapy of the primary tumor region 
(encompassing the postsurgical tumor bed including any 
residual mass plus a 10–15 mm margin) was recommended 
at 54 Gy for patients over 18 months of age preferably 
after the 4th course of chemotherapy. In patients with CSF 
dissemination at diagnosis (M1 through M4 according to 
Chang) craniospinal radiotherapy with 24 Gy plus an addi-
tional boost to the primary tumor region and any central 
nervous system (CNS) deposits was recommended for ages 
3 years and older. Circumscribed spinal deposits could be 
boosted up to 49.2 years. Innovative technologies such as 
IMRT or proton beam therapy were encouraged.
Toxicity
Toxicity was assessed according to version 3.0. of the 
Common Terminology Criteria for Adverse Events. 
Reporting of serious adverse events (SAEs) to the registry 
office was requested but not monitored.
Statistics
Overall (OS) and event- free survival (EFS) were determined 
according to Kaplan–Meier estimates. OS was defined as the 
time from diagnosis until death of any cause or the last 
visit. EFS was defined as the time from diagnosis until first 
progression, relapse, death of any cause, or last contact.
The potential impact of prognostic factors on OS and 
EFS was analyzed as follows: congenital.
Kaplan–Meier analyses were performed for basic ele-
ments such as age and metastases, tumor location, extent 
of resection, germ- line mutation (GLM), etc. Time- 
dependent factors, for example, radiotherapy (RT), complete 
remission (CR), and MT were evaluated using Cox regres-
sion for time- dependent covariates. P- values were significant 
for P ≤ 0.05. Results were considered exploratory, not 
confirmatory. Adjustment for multiple testing was not 
performed. An overall significance level was not determined 
and could not be calculated due to small numbers.
Results
Clinical characteristics of patients with AT/RT
Thirty- one patients were registered and treated according 
to Rhabdoid 2007 (Table 1). This accounts for approxi-
mately 51% of all eligible cases from Germany during 
the corresponding time (2005–2009 total incidence 
n = 61). The median age at diagnosis of 12 females and 
19 males was 20 months (range 0–120). Seventy- four 
percent of patients were below 3 years at diagnosis 
(12 < 1 years, 11 = 1 – 3 years, 8 > 3 years). Three 
congenital cases were registered. One was symptomatic 
with visible multiple synchronous extracerebral tumors 
(thorax) in addition to an AT/RT at (no. 15). A second 
presented with a visible periorbital tumor plus AT/RT at 
birth (no. 19), the third demonstrated frequent vomiting 
and hydrocephalus leading to imaging (no. 28). Tumor 
localization was infratentorial (n = 13), supratentorial 
(n = 15), or encompassed both compartments (s.t. and 
i.t. n = 3). Imaging and CSF cytology revealed six patients 
with metastases at diagnosis. Four patients presented with 
CSF dissemination (M1), one patient with additional 
intracerebral metastases (M2), and one patient with soft 
tissue metastases (M4). Analysis of CSF was completed 
in 28 patients (no analysis in no. 3, 6, 15). Patients no. 
3 and no. 6 were not stable enough for a lumbar puncture 
at diagnosis, no. 15 had multiple congenital synchronous 
tumors accompanied by soft tissue metastases (M4).
The diagnosis was centrally confirmed on tumor tissue 
in all cases except one (no. 28) with an underlying 
SMARCA4 GLM [4].
GLM were detected in six out of 21 evaluated patients. 
Five mutations affected the SMARCB1 and one the 
SMARCA4 locus (Table 2). All three patients with con-
genital tumors displayed a GLM (no. 15, 19, and 28).
Response to chemotherapy
All patients received chemotherapy according to Rhabdoid 
2007 (Fig. 1). Nine of them completed the recommended 
schedule of nine courses. Two patients received additional 
courses (no. 1, no. 25). The reasons were (no. 1) bridging 
until initiation of radiotherapy (RT) and (no. 25) com-
bination with RT for expected synergistic effects. Seven 
patients received HDCT following induction (after a dif-
ferent number of courses [range 4–8]), and one patient 
(no. 24) after completed chemotherapy (9 courses).
Thirteen patients received 2–8 courses of conventional 
chemotherapy courses. Seven patients discontinued chemo-
therapy due to disease progression, two due to toxicities 
(no. 7, 9), and one due to shunt insufficiency (no. 22). 
Three patients had started therapy according to protocols 
for different entities until definitive reference diagnosis 
was available (no. 2, 12, 17).
Twenty- eight patients received strict intraventricular 
chemotherapy. Twenty- three of these had no sign of M+ 
disease in the CSF, five patients were positive (no. 4, 8, 
14, 27, 30). Reasons for not applying intraventricular 
therapy were initiation of concomitant radiotherapy, insuf-
ficient circulation of CSF and/or CNS infections.
MT was applied to 17 patients, 14 patients did not 
receive it due to early disease progression or decision of 
the treating physician.
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Radiotherapeutic approach
Radiotherapy was applied locally to the primary tumor 
region in 23 of 31 patients. Six patients did not receive 
RT due to early disease progression, one patient due to 
age <18 months (no. 19), and one patient (no. 28) due 
to necrotizing leukoencephalopathy. The age of patients 
at the time of radiotherapy ranged from 1 to 10 years 
(Table 1). Fifteen patients were younger than 36 months 
old, and four (no. 1, 14, 18, 22) younger than 18 months 
at RT (15, 12, 15, 13 months). Two of the four patients 
died from progressive disease and one following VP- shunt 
insufficiency.
Of 23 patients who had received radiotherapy, 20 were 
diagnosed with M0 and 3 with M1 disease (no. 14, 27, 
30). One (no. 14) patient with M1 disease received only 
local radiotherapy, another patient (no. 27) craniospinal, 
and the third patient (no. 30) craniospinal and boost radio-
therapy. One had a relapse while still on therapy, the second 
is alive 5 years from diagnosis and the third died 6 years 
following diagnosis. Three of six patients with M+ (no. 4, 
8, 15) did not receive radiotherapy due to progression.
Proton beam therapy to the tumor region was applied 
to 4 patients (no. 7, 11, 14, 30) at 21, 26, 12, 63 months 
of age.
Response to therapy and outcome
A CR was achieved in 23/31 patients. Four patients pre-
sented with M1 at diagnosis (no. 8, 14, 27, 30). In 10 CR 
was achieved by neurosurgical resection (in no. 26 after 
second look surgery) and in 13 by additional chemo- and 
radiotherapy. Five patients achieved CR after two courses 
of induction, two after three courses, one after four courses, 
one after five courses, four patients thereafter.
Follow- up of survivors comprises 61–96 months FUP 
(follow- up period) with a median of 77 months. Fifteen 
patients survived, another 15 died due to disease progres-
sion/relapse and one (no. 22) following shunt insufficiency 
without signs of relapse on imaging. Only one patient 
with metastatic disease survived (no. 27), but also one 
with synchronous tumor and GLM (no. 19). Ten patients 
received a total resection and were in CR; another one 
(no. 26) after second look surgery. One of these relapsed 
(no. 1) and one (no. 4) progressed despite total resection 
and died. Among 20 patients with residual disease 
Figure 1. Rhabdoid 2007 treatment recommendation for patients with AT/RT.
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Table 2. Safety – serious adverse events recorded while treatment 
 according to the “Rhabdoid 2007” protocol.
Serious adverse events (13 SAE in 12/31 patients) n
Necrotizing leukoencephalopathy (causing therapy  
discontinuation)
1
Radiogenic gliosis 1
Sepsis (Ommaya infection n=2, post- op n=1) 7
Recurrent infections (causing therapy discontinuation) 1
Coxitis with candida 1
Pneumonia (causing discontinuation of maintenance) 1
Shunt insufficiency causing death (not due to disease) 1
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following surgery one (no. 22) died following shunt insuf-
ficiency without relapse, six eventually demonstrated pro-
gressive disease. Of 13 patients who achieved CR on 
chemotherapy seven died due to relapse 1–23 months 
after the end of therapy. Whenever feasible RT was per-
formed as a rescue measure.
Six- year overall and event- free survival rates are 46% 
(±0.10) and 45% (±0.09) resp. (Fig. 2). The latest relapse 
was 37 months following diagnosis. This patient (no. 
11) succumbed 5 years after initial diagnosis from relapse 
despite having achieved a CR to initial therapy. The 
latest death thus far occurred 72 months from diagnosis 
(no. 31).
Prognostic factors in the cohort 
Rhabdoid 2007
The Kaplan–Meier estimates for factors influencing OS 
demonstrated a significant prognostic benefit for age > 3y 
at diagnosis (P < 0.015) (Fig. 3). Of the eight patients 
who were older than 3 years at diagnosis only one relapsed 
and died (no. 30), seven are alive 61–85 months following 
diagnosis. Cox regression analysis for time- dependent 
covariates demonstrated a significant impact of radio-
therapy (P < 0.005) and achievement of a CR (P < 0.002) 
on OS (Fig. 4).
Presence of metastases at diagnosis, complete resection, 
and GLM did not influence outcome in this series. 
Intraventricular MTX or MT did not show any beneficial 
effect on OS.
Patterns of failure in AT/RT
Sixteen of 31 patients experienced treatment failure and 
all but one (death due to ventriculo- peritoneal shunt 
insufficiency) died due to disease. The median time to 
progression or relapse was 6.5 months (range 1–37 months). 
In nine patients early progression or relapse occurred 
while on therapy. The latest relapse with intracranial 
Figure 2. Overall survival and event- free survival of the Rhabdoid 2007 
cohort n = 23.
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Figure 3. Statistical analysis of prognostic factors: influence of age on 
survival.
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Figure 4. Influence of radiation therapy and achievement of complete 
remission on survival, cox model with time- dependent variates.
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metastases outside the proton radiotherapy field was 
recorded 37 months after diagnosis (no. 11). Pattern of 
progression/relapse included seven patients with progress 
disease, six local, and two combined (local + distant) 
failures.
Toxicities of therapy according  
to Rhabdoid 2007
A total of 13 SAEs were reported in 12/31 patients (Table 2). 
One treatment- related death due to insufficiency of a 
 VP- shunt and subsequent herniation of the brain was 
noted (no. 22). Three SAE led to therapy discontinuation 
due to pneumonia, recurrent infections, or necrotizing 
leukoencephalopathy associated with intraventricular MTX 
(no. 9, 23, 28).
Discussion
Challenges in the care of patients  
with AT/RT
The prognosis of patients with AT/RT remains dismal 
despite intensive multimodal therapy. Reinhard et al. 
reported a 5- year OS of 29% for 25 patients with AT/
RT [5]. Dufour et al. presented data of 58 AT/RT patients 
treated from 1998 to 2008 with a median OS of 9 months 
[7]. Comparable unfavorable results of a median OS of 
13.5 months were reported by the Canadian Pediatric 
Brain Consortium [16]. Recently, data of a first clinical 
trial in 20 patients with AT/RT indicated a promising 
2- year OS of 70%, but no follow- up data are available 
yet [8]. It appears that 5- year OS rates around 40–50% 
are achievable (S. N. Chi, pers. comm.). Rather provoca-
tive data have been published by Slavc et al. with OS 
rates of 100% in nine patients. Independent confirmation 
is currently missing [15].
Reasons for the rather limited data are the rare inci-
dence, high vulnerability of very young infants and children, 
localization in critical anatomical structures, potential for 
synchronous tumors and likelihood for chemoresistance. 
Thus, rhabdoid tumors are far from being ideal subjects 
for controlled clinical trials. Interest by pharmaceutical 
companies in performing drug trials with novel compounds 
has been sparse due to the inherent risk associated with 
mentioned factors.
The highest level of evidence will certainly be obtained 
by controlled clinical trials if possible evaluating research 
questions in a randomized fashion. However, children 
with rare diseases and a risk profile, which makes a con-
trolled trial extremely difficult, do have the same right 
for a standardized treatment with the best available 
scientific evidence of activity.
The need for comprehensive data  
sets in AT/RT
To circumvent these obstacles German oncologists and 
other investigators around the world have chosen to recruit 
patients into “registry studies.” These competence structures 
offer a system of high- quality reference diagnostics and 
expert counseling for diagnosis and therapy. The resulting 
data are inferior in quality to a controlled clinical trial, but 
superior to case series and individual reports. The reference 
system established within the GPOH has over the last dec-
ades achieved a near 99% coverage of affected children and 
is employed throughout German speaking countries.
Results of only one prospective clinical trial have been 
published in AT/RT [8]. At the time of initiation of the 
EU- RHAB registry in 2005 a standard of therapy had not 
been consented. As a European group we therefore chose 
the means of a registry. It has by now been joined by 
several European countries and has continued collecting 
data for almost 10 years. This modality was meant to 
bridge the gap between case series and the start of a 
clinical trial not to lose valuable data. The EU- RHAB 
database allows conclusions on prognostic factors, course 
of disease and treatment modalities, onto which together 
with the diagnostic reference structure future phase I/II 
clinical trials will be built.
As expected there were deviations from to the protocol 
according to clinical conditions and individual preferences. 
The resulting groups with small numbers may not provide 
statistical significance and the results are complex to inter-
pret. Despite these facts Rhabdoid 2007 therapy resulted 
in 6- year OS and EFS rates of 46% (±0.10) and 45% 
(±0.09). This is an acceptable outcome when compared 
with published data and is based on a relevant follow- up 
period of median of 6 years (5–8 years).
The prognostic variables determining 
outcome in AT/RT
Results from the registry study Rhabdoid 2007 provide 
information of prognostic factors in accordance with those 
previously described such as age at diagnosis [6, 7, 17]. 
In our cohort seven of eight patients older than 3 years 
at diagnosis are long- term survivors. Furthermore, Cox 
regression analysis for time- dependent covariates demon-
strated that a CR and the application of radiotherapy 
were positive prognostic factors. As described by Chi et al. 
CR by primary tumor therapy seems to be an important 
prognostic factor for survival [8, 18]. Our analyses con-
firmed this finding. In the current cohort all surviving 
patients (n = 15) had achieved a CR. Nevertheless, of 23 
who had achieved CR eight patients experienced late 
relapses and died.
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Another negative prognostic factor appears to be the 
presence of GLM [19]. Affected patients generally have a 
rather poor prognosis with a 2- year survival of 29% [19]. 
However, detailed data have recently been reported on four 
patients, including two of ours (no. 19, 25), with a pre-
disposition to rhabdoid tumors and EFS of 5 and 7 years 
from diagnosis [14]. In our cohort, no influence of GLM 
on OS was detected. However, only six patients had GLM, 
two of them are long- term survivors (no. 19, 25). Two 
further cases in our cohort showed an unexpected long 
survival despite unfavorable prognostic factors. One patient 
with M1 is still alive more than 5 years from diagnosis 
(no. 27) and another patient survived recurrence for 
22 months until death of disease (no. 11). These cases 
indicate that even in unfavorable situations a therapeutic 
attempt is justified and could result in an unexpected sur-
vival time.
In our cohort there was a high likelihood of survival 
once patients reached 3 years from diagnosis without 
relapse. The latest relapse occurred 37 months after diag-
nosis (no. 11) and the follow- up in our cohort ranged 
from 60 up to 96 months. Still, the literature knows of 
a case of late intracranial recurrence 5.5 years following 
diagnosis [20]. The majority of our patients experiencing 
treatment failure progressed on therapy, which indicates 
chemotherapy resistance. Especially those patients will most 
likely not benefit from further intensification of treatment 
but rather from agents targeting specific pathways. Since 
all relapsed patients in our cohort died, there is an evident 
need for relapse trials with innovative concepts in AT/RT.
The potential role of radiotherapy in the 
treatment of AT/RT
Radiotherapy has been deemed to be a significant positive 
prognostic factor on retrospective analyses [17]. The NCI 
identified RT as an independent factor for survival in 
retrospective analysis of 144 children with AT/RT [21]. 
It was concluded that RT could be of significant benefit 
particularly when looking at very young children <3 years. 
For our cohort the multivariate, time- dependent statistical 
analysis demonstrated a significant beneficial effect of RT 
on OS and 60% of irradiated patients were <3 years. 
Assessment of the true value of RT in our cohort is 
complicated by the fact that most patients who did not 
receive RT were below 1 year of age at diagnosis and 
experienced rapid progressive disease. As a majority of 
progressions occurred on chemotherapy it deserves discus-
sion whether RT as a rescue measure should be given 
earlier, for example, even to patients below 18 months 
of age [22]. Late effects of RT in young children are, 
however, significant and have to be considered when tai-
loring treatment concepts [23]. Increasingly, modern 
technologies like proton beam therapy are used and recent 
reports demonstrate both good feasibility and promising 
local control rates [24, 25].
The role of single therapeutic components in the con-
cept of multimodal therapy such as HDCT, intraventricular 
MTX and MT remains to be clarified. In our cohort the 
analysis of these three modalities showed no beneficial 
effect on OS. Data from 19 patients with HDCT of the 
EU- RHAB registry have been published [10] but due to 
the retrospective nature and a heterogeneously treated 
group with small patient numbers, no definitive conclu-
sion about the effect of HDCT as primary therapy for 
AT/RT may be drawn.
Feasibility of intensive multimodal therapy 
in children with AT/RT
Despite a major proportion of >70% of patients below 
the age of 3 years in our cohort, including 35% infants, 
no toxic death due to chemotherapy or RT occurred. 
One treatment- related death was reported following VP- 
shunt insufficiency. In three cases (no. 7, 9, 22) early 
termination of chemotherapy was necessary due to com-
plications of chemotherapy and intraventricular MTX. 
With respect to the young age of the patient population 
and treatment intensity, the recommended treatment of 
Rhabdoid 2007 showed feasibility and safety. Still, a poten-
tial for underreporting of adverse events due to the vol-
untary character in the framework of the registry has to 
be acknowledged.
Possible late sequelae which are recognized after intensive 
therapy for other malignancies in early childhood [26] 
will be investigated more detailed in AT/RT patients in 
the future.
Conclusion
Our results demonstrate that intensive multimodality treat-
ment is feasible, safe and efficient even in very young 
patients. This supports the concept of EU- RHAB as the 
basis for data analysis but also for future clinical trials 
in first line and relapse therapies. The implementation of 
a phase I/II study for AT/RT and other rhabdoid tumors 
in the frame of the established registry structures of EU- 
RHAB is essential for further improvement of survival. 
Recently detected pathogenic mechanisms such as epige-
netic modulation should give clues which compounds to 
choose for future innovative trials [27].
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